Global Markets

36.1% of patients on new Wegovy (NOVOB DC) weight-loss pill have no prior experience on a GLP-1 drug, new study finds; Among patients on new Wegovy pill, 21.1% switched from injectable wegovy, 15.8% switched from injectable zepbound

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more